CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif. – Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health, today reported first patients dosed in the AMPLIFY Phase 2 clinical trial for HU6, a potential best-in-class oral MASH therapy. “We are excited to dose the first patients in our AMPLIFY...

REDWOOD CITY, Calif. — Hinge Bio, Inc., a privately-held clinical-stage biotechnology company focused on the discovery and development of innovative antibody therapeutics, referred to as “GEM-DIMERs™”, announced the successful dosing of the first participants in one of its Phase 1 clinical trials of HB2198, the Company’s lead multispecific product candidate targeting...

AUSTIN, Texas — TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to TOBY’s urine-based Multi-Cancer Early Detection (MCED) test. The designation recognizes the test’s potential to enable earlier detection of multiple cancers through a...